335 related articles for article (PubMed ID: 17409414)
21. Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts.
Martinelli G; Ottaviani E; Buonamici S; Isidori A; Borsaru G; Visani G; Piccaluga PP; Malagola M; Testoni N; Rondoni M; Nucifora G; Tura S; Baccarani M
Haematologica; 2003 Nov; 88(11):1221-8. PubMed ID: 14607750
[TBL] [Abstract][Full Text] [Related]
22. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide.
Shackelford D; Kenific C; Blusztajn A; Waxman S; Ren R
Cancer Res; 2006 Dec; 66(23):11360-9. PubMed ID: 17145882
[TBL] [Abstract][Full Text] [Related]
23. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
Haas K; Kundi M; Sperr WR; Esterbauer H; Ludwig WD; Ratei R; Koller E; Gruener H; Sauerland C; Fonatsch C; Valent P; Wieser R
Genes Chromosomes Cancer; 2008 Apr; 47(4):288-98. PubMed ID: 18181178
[TBL] [Abstract][Full Text] [Related]
24. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression.
Ohyashiki JH; Ohyashiki K; Shimamoto T; Kawakubo K; Fujimura T; Nakazawa S; Toyama K
Blood; 1995 Jun; 85(12):3713-8. PubMed ID: 7780155
[TBL] [Abstract][Full Text] [Related]
25. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
Lugthart S; van Drunen E; van Norden Y; van Hoven A; Erpelinck CA; Valk PJ; Beverloo HB; Löwenberg B; Delwel R
Blood; 2008 Apr; 111(8):4329-37. PubMed ID: 18272813
[TBL] [Abstract][Full Text] [Related]
26. Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT.
Liu Y; Chen L; Ko TC; Fields AP; Thompson EA
Oncogene; 2006 Jun; 25(25):3565-75. PubMed ID: 16462766
[TBL] [Abstract][Full Text] [Related]
27. SnoN overexpression is predictive of poor survival in patients with esophageal squamous cell carcinoma.
Akagi I; Miyashita M; Makino H; Nomura T; Hagiwara N; Takahashi K; Cho K; Mishima T; Takizawa T; Tajiri T
Ann Surg Oncol; 2008 Oct; 15(10):2965-75. PubMed ID: 18612694
[TBL] [Abstract][Full Text] [Related]
28. Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements.
Sitailo S; Sood R; Barton K; Nucifora G
Leukemia; 1999 Nov; 13(11):1639-45. PubMed ID: 10557037
[TBL] [Abstract][Full Text] [Related]
29. Copy number amplification of 3q26-27 oncogenes in microdissected oral squamous cell carcinoma and oral brushed samples from areca chewers.
Lin SC; Liu CJ; Ko SY; Chang HC; Liu TY; Chang KW
J Pathol; 2005 Aug; 206(4):417-22. PubMed ID: 15906274
[TBL] [Abstract][Full Text] [Related]
30. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
[TBL] [Abstract][Full Text] [Related]
32. EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22.
De Weer A; Speleman F; Cauwelier B; Van Roy N; Yigit N; Verhasselt B; De Moerloose B; Benoit Y; Noens L; Selleslag D; Lippert E; Struski S; Bastard C; De Paepe A; Vandenberghe P; Hagemeijer A; Dastugue N; Poppe B;
Haematologica; 2008 Dec; 93(12):1903-7. PubMed ID: 18815193
[TBL] [Abstract][Full Text] [Related]
33. Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI1 gene in two cases of CML-BC with inv(3)(q21q26).
Suzukawa K; Taki T; Abe T; Asoh H; Kamada N; Yokota J; Morishita K
Genomics; 1997 Jun; 42(2):356-60. PubMed ID: 9192861
[TBL] [Abstract][Full Text] [Related]
34. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
Cuenco GM; Ren R
Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
[TBL] [Abstract][Full Text] [Related]
35. Comparative expression analysis of the antagonistic transcription factors EVI1 and MDS1-EVI1 in murine tissues and during in vitro hematopoietic differentiation.
Wimmer K; Vinatzer U; Zwirn P; Fonatsch C; Wieser R
Biochem Biophys Res Commun; 1998 Nov; 252(3):691-6. PubMed ID: 9837768
[TBL] [Abstract][Full Text] [Related]
36. The transcription factor evi-1 is overexpressed, promotes proliferation, and is prognostically unfavorable in infratentorial ependymomas.
Koos B; Bender S; Witt H; Mertsch S; Felsberg J; Beschorner R; Korshunov A; Riesmeier B; Pfister S; Paulus W; Hasselblatt M
Clin Cancer Res; 2011 Jun; 17(11):3631-7. PubMed ID: 21493867
[TBL] [Abstract][Full Text] [Related]
37. TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.
Yokoi S; Yasui K; Iizasa T; Imoto I; Fujisawa T; Inazawa J
Clin Cancer Res; 2003 Oct; 9(13):4705-13. PubMed ID: 14581340
[TBL] [Abstract][Full Text] [Related]
38. Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.
Sayadi A; Jeyakani J; Seet SH; Wei CL; Bourque G; Bard FA; Jenkins NA; Copeland NG; Bard-Chapeau EA
Oncogene; 2016 May; 35(18):2311-21. PubMed ID: 26234679
[TBL] [Abstract][Full Text] [Related]
39. Deletion of sequences telomeric of the EVI1 gene in 3q26 associated with a novel pericentric inv(3)(p25q26) in a patient with acute myelogenous leukemia.
Wieser R; Lechner K; Valent P; Fonatsch C
Haematologica; 2003 Dec; 88(12):1427-9. PubMed ID: 14688000
[No Abstract] [Full Text] [Related]
40. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.
Sood R; Talwar-Trikha A; Chakrabarti SR; Nucifora G
Leukemia; 1999 Mar; 13(3):348-57. PubMed ID: 10086725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
